1. What is the innovation?

Clarity is a personalised medicine company focused on the treatment of serious diseases. The company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

Clarity’s platform SAR Technology allows peptides and antibodies to be radiolabelled for visualisation using PET imaging and therapy. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach by only treating those patients that are likely to respond to therapy and excluding those that won’t. This precision medicine approach is at the forefront of drug development.

2. What benefits does the innovation bring?

Clarity develops personalised medicine diagnostic imaging and therapeutic products. By using its proprietary technology, Clarity is developing next-generation theranostic (diagnostic and therapy) solutions for serious diseases, such as cancer, that are not well treated by current therapies.

3. What commercial success and/or benefit to society has it achieved?

SAR Technology is at the core of Clarity’s in-house drug development program, with its first drug SARTATE™, an oncology theranostic (diagnostic and therapy), in clinical trials for meningioma and neuroendocrine tumours in adult patients. SARTATE™ will also potentially allow better treatment of paediatric cancers and is in clinical trials for neuroblastoma, an aggressive childhood cancer. Clarity will complete the clinical and commercial development of SARTATE™ as a product and further realise the potential of other pipeline products using Clarity’s platform SAR Technology in other cancers.

4. What lessons learnt can you share?

Clarity’s focus since the beginning has been to collaborate with academics and clinicians in Australia to build out expertise in the fields of nuclear medicine and biotechnology. The outcome of this is the development of better cancer therapies for the treatment of cancers in adults and children.

Clarity’s SAR Technology has been licenced from the Australian Nuclear Science and Technology Organisation (ANSTO) and the University of Melbourne. Clarity continues to collaborate with both groups to develop further products to treat a broader range of cancers.

Clarity also has strong relationships with clinical organisations, the most important being the Peter MacCallum Cancer Centre, where Clarity’s technology has been translated into human clinical trials and where the majority of our pre-clinical work has been completed. Clarity also has collaborations with the University of Queensland, Monash University, Auspep, Baker Heart and Diabetes Institute, South Australian Health and Medical Research Institute, Children’s Hospital at Westmead, Idaho Accelerator Center, Memorial Sloan Kettering Cancer Center, Washington University in St Louis, Boston Children’s Hospital and Harvard Medical School.

5. How many new jobs has this innovation created?

20